Clinical trial · Observational
Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)
NCT07279948CI-TRIAL-00120334LUSIPnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
A prospective, longitudinal, single-arm interventional study of lung cancer screening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- • Proportion of negative cases on screening according to the Lung-RADS classification.
- timeFrame
- Last 10 years
- description
- Tomographic screening for lung cancer in a population with a high prevalence of granulomatous disease may increase the proportion of false-positive cases, leading to unnecessary medical procedures, resource waste, and patient risk. This epidemiological scenario may also result in an increase in cases classified as benign or probably benign in screening.
- measure
- • Proportion of false-positives.
- timeFrame
- Last 10 years
- description
- Tomographic screening for lung cancer in a population with a high prevalence of granulomatous disease may increase the proportion of false-positive cases, leading to unnecessary medical procedures, resource waste, and patient risk. This epidemiological scenario may also result in an increase in cases classified as benign or probably benign in screening.
Secondary outcomes (7)
- measure
- • Cancer detection rate.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria:
In order, to be eligible for the study, patients must fulfill all the following inclusion criteria:
* Age between ≥50 and ≤80 years.
* Be a current smoker or have quit 15 years ago or less.
* Have participated or are currently participating in smoking cessation program.
* Lifetime smoking exposure equal to or greater than 20 pack-year.
* Provided signed informed consent (ICF)
Exclusion Criteria:
* In order, to be exclude for the study, patients must at least one of the following exclusion criteria:
* Contraindications to the screening examination: (claustrophobic or weighing more than 130 kgs).
* Inability to climb 3 stair steps non-stop (36 steps).
* Disabling dyspnea
* Symptomatic (with signs and symptoms suspicious of breast cancer lung, namely):
* pleuritic chest pain
* rapidly progressive dyspnea of recent onset
* hemoptysis
* unexplained hoarseness, lasting more than 1 month.
* bone pain
* supraclavicular lymphadenopathy or cervical lymphadenopathy persistent
* unexplained weight loss of 5% or more of weight in less than 6 months
* Previous history of malignant neoplasm (excluding non-melanoma skin cancer) diagnosed less than 10 years before the date of the interview;
* Patients with diagnostic of severe psychiatric disease
* Immunosuppressed by illness or drugs.
* Subjected to anterior lung resection even when determined due to an etiology other than malignant neoplasia.
* Person with a serious terminal illness that contraindicates curative lung surgery.References
Publications (0)
Data not yet available
No reference posted for this study.